New guidelines for the diagnosis and treatment of neurocysticercosis: a difficult proposal for patients in endemic countries

References

• Welburn SC, Beange I, Ducrotoy MJ, et al. The neglected zoonoses–the case for integrated control and advocacy. Clin Microbiol Infect. 2015;21:433–443.
   PubMed Web of Science ®Google Scholar
• Roman G, Sotelo J, Del Brutto O, et al. A proposal to declare neurocysticercosis an international reportable disease. Bull World Health Organ. 2000;78:399–406.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Taeniasis/cysticercosis fact sheet. Geneva, Switzerland: World Health Organization; 2017. [cited 2018 Jun 1]. Available from: http://www.who.int/mediacentre/factsheets/fs376/en/
   Google Scholar
• O’Keefe KA, Eberhard ML, Shafir SC, et al. Cysticercosis-related hospitalizations in the United States, 1998-2011. Am J Trop Med Hyg. 2015;92:354–359.
   PubMed Web of Science ®Google Scholar
• O’Neal SE, Flecker RH. Hospitalization frequency and charges for neurocysticercosis, United States, 2003-2012. Emerg Infect Dis. 2015;21:969–976.
   PubMed Web of Science ®Google Scholar
• Del Brutto OH. A review of cases of human cysticercosis in Canada. Can J Neurol Sci. 2012;39:319–322.
   PubMed Web of Science ®Google Scholar
• Momčilović S, Cantacessi C, Arsić-Arsenijević V, et al. Rapid diagnosis of parasitic diseases: current scenario and future needs. Clin Microbiol Infect. 2018. pii: S1198-743X(18)30395-1. Epub ahead of print. DOI:10.1016/j.cmi.2018.04.028
   PubMedGoogle Scholar
• Carabin H, Ndimubanzi PC, Budke CM, et al. Clinical manifestations associated with neurocysticercosis: a systematic review. PLoS Negl Trop Dis. 2011;5:e1152.
   PubMed Web of Science ®Google Scholar
• Winkler AS, Richter H Landscape analysis: management of neurocysticercosis with an emphasis on low- and middle-income countries. Commissioned by the World Health Organization; 2015. Available from: http://apps.who.int/iris/bitstream/10665/152896/1/WHO_HTM_NTD_NZD_2015.05_eng.pdf
   Google Scholar
• Fleury A, Sastre P, Sciutto E, et al. A lateral flow assay (LFA) for the rapid detection of extraparenchymal neurocysticercosis using cerebrospinal fluid. Exp Parasitol. pii: S0014-4894(16)30277-6. 2016;171:67–70. Epub ahead of print.
   Web of Science ®Google Scholar
• Parkhouse RME, Carpio A, Campoverde A, et al. Reciprocal contribution of clinical studies and the HP10 antigen ELISA for the diagnosis of extraparenchymal neurocysticercosis. Acta Trop. 2017;178:119–123.
   PubMed Web of Science ®Google Scholar
• Carpio A, Fleury A, Romo ML, et al. Neurocysticercosis: the good, the bad, and the missing. Expert Rev Neurother. 2018;14:1–13.
   Google Scholar
• Carpio A, Fleury A, Romo ML, et al. New diagnostic criteria for neurocysticercosis: reliability and validity. Ann Neurol. 2016;80:434–442.
   PubMed Web of Science ®Google Scholar
• Baird RA, Wiebe S, Zunt JR, et al. Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;80:1424–1429.
   PubMed Web of Science ®Google Scholar
• Abba K, Ramaratnam S, Ranganathan LN. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev. 2010;17:CD000215.
   Google Scholar
• Göngora-Rivera F, Soto-Hernández JL, González Esquivel D, et al. Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology. 2006;66:436–438.
   PubMed Web of Science ®Google Scholar
• White AC Jr., Coyle CM, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018;66:1159–1163.
   PubMedGoogle Scholar
• Cardona-Arias JA, Carrasquilla-Agudelo YE, Restrepo-Posada DC. Validity of three methods for inmuno-diagnostic of neurocysticercosis: systematic review of the literature with meta-analysis 1960-2014. Rev Chilena Infectol. 2017;34:33–44.
   PubMed Web of Science ®Google Scholar
• Abraham R, Pardini AX, Vaz AJ, et al. Taenia antigen detection in the CSF of patients with neurocysticercosis and its relationship with clinical activity of the disease. Arq Neuropsiq. 2004;62:756–760. Available from: https://www.ncbi.nlm.nih.gov/pubmed/?term=Livramento%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=15476063
   PubMed Web of Science ®Google Scholar
• Sisson P Why our health care costs so much — and why fixes aren’t likely. The San Diego Union Tribune. San Diego, California: San Diego Union-Tribune, LLC. 2017. Available from: http://www.sandiegouniontribune.com/news/health/sd-me-healthcare-costs-20170318-story.html
   Google Scholar
• Garcia HH, Gonzales I, Lescano AG, et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014;14:687–695.
   PubMed Web of Science ®Google Scholar
• Casazza G, Casella F, Gruppo di Autoformazione M. Can we trust in trials stopped early for benefit? Intern Emerg Med. 2012;7:559–561.
   PubMed Web of Science ®Google Scholar
• Sotelo J, Marin C. Hydrocephalus secondary to cysticercotic arachnoiditis. a long-term follow-up review of 92 cases. J Neurosurg. 1987;66:686–689.
   PubMed Web of Science ®Google Scholar
• Martins-Melo FR, Ramos AN Jr, Cavalcanti MG, et al. Neurocysticercosis-related mortality in Brazil, 2000-2011: epidemiology of a neglected neurologic cause of death. Acta Trop. 2016;153:128–136.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health (NIH). Albendazole. Livertox Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: National Institutes of Health; 2018. Available from: https://livertox.nih.gov/Albendazole.htm
   Google Scholar
• Carpio A. Neurocysticercosis: an update. Lancet Infect Dis. 2002;2:751–762.
   PubMed Web of Science ®Google Scholar
• Tellez-Zenteno JF, Hernandez-Ronquillo L. Epidemiology of neurocysticercosis and epilepsy, is everything described? Epilepsy Behav. 2017;76:146–150.
   PubMed Web of Science ®Google Scholar
• Gripper LB, Welburn SC. The causal relationship between neurocysticercosis infection and the development of epilepsy – a systematic review. Infect Dis Poverty. 2017;6:31.
   PubMed Web of Science ®Google Scholar
• Devleesschauwer B, Allepuz A, Dermauw V, et al. Taenia solium in Europe: still endemic? Acta Trop. 2017;165:96–99.
   PubMed Web of Science ®Google Scholar
• Symeonidou I, Arsenopoulos K, Tzilves D, et al. Human taeniasis/cysticercosis: a potentially emerging parasitic disease in Europe. Ann Gastroenterol. 2018;31:406–1212.
   PubMed Web of Science ®Google Scholar